Literature DB >> 28242648

Identification of Novel Chondroprotective Mediators in Resolving Inflammatory Exudates.

Magdalena K Kaneva1, Karin V Greco2, Sarah E Headland2, Trinidad Montero-Melendez2, Prashant Mori3, Kevin Greenslade3, Costantino Pitzalis2, Adrian Moore3, Mauro Perretti1.   

Abstract

We hypothesized that exudates collected at the beginning of the resolution phase of inflammation might be enriched for tissue protective molecules; thus an integrated cellular and molecular approach was applied to identify novel chondroprotective bioactions. Exudates were collected 6 h (inflammatory) and 24 h (resolving) following carrageenan-induced pleurisy in rats. The resolving exudate was subjected to gel filtration chromatography followed by proteomics, identifying 61 proteins. Fractions were added to C28/I2 chondrocytes, grown in micromasses, ions with or without IL-1β or osteoarthritic synovial fluids for 48 h. Three proteins were selected from the proteomic analysis, α1-antitrypsin (AAT), hemopexin (HX), and gelsolin (GSN), and tested against catabolic stimulation for their effects on glycosaminoglycan deposition as assessed by Alcian blue staining, and gene expression of key anabolic proteins by real-time PCR. In an in vivo model of inflammatory arthritis, cartilage integrity was determined histologically 48 h after intra-articular injection of AAT or GSN. The resolving exudate displayed protective activities on chondrocytes, using multiple readouts: these effects were retained in low m.w. fractions of the exudate (46.7% increase in glycosaminoglycan deposition; ∼20% upregulation of COL2A1 and aggrecan mRNA expression), which reversed the effect of IL-1β. Exogenous administration of HX, GSN, or AAT abrogated the effects of IL-1β and osteoarthritic synovial fluids on anabolic gene expression and increased glycosaminoglycan deposition. Intra-articular injection of AAT or GSN protected cartilage integrity in mice with inflammatory arthritis. In summary, the strategy for identification of novel chondroprotective activities in resolving exudates identified HX, GSN and AAT as potential leads for new drug discovery programs.
Copyright © 2017 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Year:  2017        PMID: 28242648     DOI: 10.4049/jimmunol.1601111

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  4 in total

1.  Low Admission Plasma Gelsolin Concentrations Identify Community-acquired Pneumonia Patients at High Risk for Severe Outcomes.

Authors:  Wesley H Self; Richard G Wunderink; Mark J DiNubile; Thomas P Stossel; Susan L Levinson; Derek J Williams; Evan J Anderson; Anna M Bramley; Seema Jain; Kathryn M Edwards; Carlos G Grijalva
Journal:  Clin Infect Dis       Date:  2019-09-13       Impact factor: 9.079

2.  Synovial fluid proteome changes in ACL injury-induced posttraumatic osteoarthritis: Proteomics analysis of porcine knee synovial fluid.

Authors:  Ata M Kiapour; Jakob T Sieker; Benedikt L Proffen; TuKiet T Lam; Braden C Fleming; Martha M Murray
Journal:  PLoS One       Date:  2019-03-01       Impact factor: 3.240

3.  Extracellular vesicles from monocyte/platelet aggregates modulate human atherosclerotic plaque reactivity.

Authors:  Silvia Oggero; Monica de Gaetano; Simone Marcone; Stephen Fitzsimons; Andreia L Pinto; Dinara Ikramova; Mary Barry; David Burke; Trinidad Montero-Melendez; Dianne Cooper; Thomas Burgoyne; Orina Belton; Lucy V Norling; Eoin P Brennan; Catherine Godson; Mauro Perretti
Journal:  J Extracell Vesicles       Date:  2021-04-27

4.  Production and Secretion of Gelsolin by Both Human Macrophage- and Fibroblast-like Synoviocytes and GSN Modulation in the Synovial Fluid of Patients with Various Forms of Arthritis.

Authors:  Jessica Feldt; Martin Schicht; Jessica Welss; Kolja Gelse; Stefan Sesselmann; Michael Tsokos; Eileen Socher; Fabian Garreis; Thomas Müller; Friedrich Paulsen
Journal:  Biomedicines       Date:  2022-03-21
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.